Barr Laboratories, Inc. and Galen Holdings PLC have announced that they have signed a letter of intent for Barr to acquire the exclusive rights in the United States and Canada for Loestrin(R) and Loestrin(R) FE oral contraceptive products. The proposed transaction also would include a settlement of pending litigation between Barr and Galen regarding Galen’s Read more about Letters Of Intent Signed For Barr To Acquire Rights To Galen’s Loestrin(r) Oral Contraceptive Product[…]